Psoriatic Arthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (NSAIDs, DMARDs, Biologics, Others), By Route of Administration (Topical, Oral, Injectable), By Region and Competition, 2020-2030F

Market Overview

Global Psoriatic Arthritis Treatment Market was valued at USD 9.78 Billion in 2024 and is expected to reach USD 13.48 Billion by 2030 with a CAGR of 5.69%. This is driven by advancements in drug development, rising disease awareness, and improvements in diagnostic capabilities. As healthcare systems around the world increasingly recognize the impact of psoriatic arthritis on quality of life and productivity, treatment options are expanding to meet the evolving needs of patients.

Biologic therapies remain the cornerstone of treatment in this market, offering targeted approaches that help control inflammation and prevent joint damage. These therapies are particularly effective for patients with moderate to severe disease and have become widely adopted in both developed and emerging regions. Innovation continues to be a critical factor in shaping the future of this market. Pharmaceutical companies are investing in next-generation therapies that offer improved safety profiles, reduced dosing frequency, and enhanced patient adherence.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry is playing a pivotal role in driving the growth of the psoriatic arthritis treatment market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. The most substantial and profitable segments within the sector are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which generate over USD 400 billion. With increasing investments in healthcare infrastructure, rising patient awareness, and improved access to specialized care, the demand for effective treatment solutions for chronic autoimmune conditions like psoriatic arthritis is steadily rising.

As healthcare systems across both developed and emerging markets evolve, there is greater emphasis on early diagnosis, personalized medicine, and long-term disease management. More than 200,000 Ayushman Arogya Mandirs have been established nationwide to support early diagnosis and treatment. These centers provide millions of citizens with convenient access to screenings for diseases such as cancer, hypertension, and diabetes. This shift is particularly significant for psoriatic arthritis, a complex and progressive condition that requires comprehensive and sustained treatment strategies. The availability of advanced biologics, targeted therapies, and disease-modifying anti-rheumatic drugs (DMARDs) has expanded significantly as part of this healthcare evolution.

Surge in Technological Advancements

The global psoriatic arthritis treatment market is witnessing robust growth, largely fueled by a surge in technological advancements across biopharmaceutical research, diagnostics, and drug delivery systems. Innovations in biologics and targeted therapies, particularly TNF inhibitors and IL-17/IL-23 inhibitors, have significantly improved patient outcomes, offering more effective and personalized treatment options with fewer side effects.

Breakthroughs in genomics, proteomics, and precision medicine are enabling earlier and more accurate diagnosis of psoriatic arthritis, facilitating timely intervention and better disease management. This has led to an increased demand for advanced therapeutics capable of slowing disease progression and improving quality of life. A notable innovation has been the development of a bispecific inhibitor targeting both TNF (TNFi) and IL-17, utilizing a targeted variable domain immunoglobulin. This approach leverages the established efficacy of each cytokine in the treatment of psoriatic arthritis (PsA).

Download Free Sample Report

Key Market Challenges

High Treatment Costs & Financial Accessibility

One of the foremost challenges confronting the Global Psoriatic Arthritis (PsA) Treatment Market is the high cost associated with advanced therapies, particularly biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). These innovative treatments, while clinically effective, command significant pricing often reaching tens of thousands of dollars annually per patient. This elevated cost structure poses substantial barriers to patient access, especially in emerging economies and underfunded healthcare systems.

The financial burden not only limits market penetration but also affects patient adherence and long-term treatment outcomes. Payers and insurers are increasingly scrutinizing reimbursement criteria, imposing stringent prior authorization processes that further complicate access. Consequently, patients may experience delays or outright denial of coverage for these essential therapies.

Key Market Trends

Rise of Biologics & Targeted Therapies

The global psoriatic arthritis treatment landscape is witnessing a significant transformation driven by the rapid adoption of biologics and targeted therapies. These advanced treatment modalities have emerged as the cornerstone of disease management, owing to their ability to specifically target underlying inflammatory pathways with enhanced efficacy and safety profiles compared to conventional therapies.

Biologics, including tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17, and IL-23 inhibitors, currently command a substantial share of the market, reflecting their growing acceptance among clinicians and patients alike. In June 2025, Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili (aflibercept). Yesafili, a biosimilar to Eylea (aflibercept) injection, is available in vial and prefilled syringe formats at a concentration of 2 mg/0.05 mL. This marks the first approval by Health Canada of a biosimilar to Eylea. Their precision mechanism of action not only improves clinical outcomes but also contributes to better quality of life for patients suffering from psoriatic arthritis.

Segmental Insights

Drug Class Insights

Based on Drug Class, NSAIDs have emerged as the fastest growing segment in the Global Psoriatic Arthritis Treatment Market in 2024. This is because they offer effective and rapid relief from inflammation, pain, and swelling associated with the condition. Their cost-effectiveness compared to more advanced biologic treatments makes them accessible to a broader range of patients, particularly in emerging markets where affordability is a critical factor. Additionally, NSAIDs are widely available and can often be obtained over-the-counter, which enhances their convenience and market penetration.

Route of Administration Insights

Based on Route of Administration, Topical have emerged as the fastest growing segment in the Global Psoriatic Arthritis Treatment Market during the forecast period. This is due to their ability to provide targeted relief directly to affected areas. This localized approach minimizes systemic side effects, making topical therapies a safer and more attractive option for many patients. Additionally, their ease of use contributes to better patient compliance, as individuals are more likely to consistently follow treatment regimens that are non-invasive and straightforward. Recent advancements in forsmulation technologies have further improved the effectiveness of topical treatments by enhancing drug absorption and action at the site of inflammation.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Psoriatic Arthritis Treatment Market in 2024. This is due to a combination of several strategic factors. The region benefits from a highly advanced healthcare infrastructure, which ensures widespread access to specialized medical services and facilitates accurate diagnosis and effective management of psoriatic arthritis. Additionally, North America is home to many of the world’s leading pharmaceutical and biotechnology companies, fostering innovation and the rapid introduction of new, effective treatment options.

Recent Development

• In June 2025, Johnson & Johnson announced Phase 3b APEX study results showing that TREMFYA (guselkumab) significantly reduced signs and symptoms of active psoriatic arthritis (PsA) and inhibited joint structural damage progression at 24 weeks versus placebo. These late-breaking findings are among 30 presentations Johnson & Johnson is highlighting at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress. Notably, guselkumab is the only IL-23 inhibitor in its class to demonstrate prevention of structural damage progression, offering new clinical insights and emphasizing the need for safe, effective treatments addressing the full disease burden.
• In April 2025, Takeda introduced a new oral treatment for psoriatic arthritis—a selective TYK2 inhibitor. Building on the success of JAK inhibitors, this therapy offers more targeted inhibition by specifically focusing on the TYK2 pathway, a key regulator of the immune system. Unlike broader JAK inhibitors, TYK2 inhibition provides greater selectivity, potentially minimizing side effects while maintaining efficacy. Clinical trials assessed multiple doses (5 mg, 15 mg, and 30 mg), with the 15 mg and 30 mg doses demonstrating significant clinical improvements.
• In July 2025, The Chinese University of Hong Kong (CUHK) Faculty of Medicine announced that inhibiting interleukin-17 (IL-17), a protein produced by immune cells, can prevent bone damage in psoriatic arthritis (PsA) patients. Utilizing advanced imaging technology to monitor joint damage over time, researchers demonstrated that secukinumab, a biologic IL-17 inhibitor, shows potential in promoting partial erosion repair and preventing enthesiophyte progression in PsA patients.
• In 2025, NHS Forth Valley launched a new clinical trial at Forth Valley Royal Hospital to provide local patients access to an innovative treatment for psoriatic arthritis. The study aims to assess the safety and efficacy of a novel drug designed to reduce joint pain and swelling while improving disease control in patients with active psoriatic arthritis. This trial underscores NHS Forth Valley’s commitment to advancing medical research and expanding access to cutting-edge therapies. With an increasing number of clinical trials across various specialties, patients are encouraged to discuss research participation opportunities with their healthcare providers.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Pfizer, Inc.
• UCB S.A.

Report Scope

In this report, the Global Psoriatic Arthritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Psoriatic Arthritis Treatment Market, By Drug Class:

o   NSAIDs

o   DMARDs

o   Biologics

o   Others

• Psoriatic Arthritis Treatment Market, By Route of Administration:

o   Topical

o   Oral

o   Injectable

• Psoriatic Arthritis Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriatic Arthritis Treatment Market.

Available Customizations:

Global Psoriatic Arthritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Psoriatic Arthritis Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]